☰

Paul Trippier - Publications

Affiliations: 
Pharmaceutical Sciences Texas Tech University Health Sciences Center 
Tree Info Grants Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Zhang Y, Sharma S, Jonnalagadda S, Kumari S, Queen A, Esfahani SH, Archie SR, Nozohouri S, Patel D, Trippier PC, Karamyan VT, Abbruscato TJ. Discovery of the Next Generation of Non-peptidomimetic Neurolysin Activators with High Blood-Brain Barrier Permeability: a Pharmacokinetics Study in Healthy and Stroke Animals. Pharmaceutical Research. PMID 37833570 DOI: 10.1007/s11095-023-03619-5  0.729
2023 Huwaimel BI, Jonnalagadda SK, Jonnalagadda S, Kumari S, Nocentini A, Supuran CT, Trippier PC. Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold. Drug Development Research. PMID 36872587 DOI: 10.1002/ddr.22049  0.713
2022 Huwaimel BI, Jonnalagadda S, Jonnalagadda S, Zahra FT, Nocentini A, Supuran CT, Mikelis CM, Trippier PC. Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation. Bioorganic & Medicinal Chemistry. 67: 116805. PMID 35635929 DOI: 10.1016/j.bmc.2022.116805  0.733
2022 Jonnalagadda SK, Huwaimel BI, Jonnalagadda S, Garrison JC, Trippier PC. Access to Highly Strained Tricyclic Ketals Derived from Coumarins. The Journal of Organic Chemistry. 87: 4476-4482. PMID 35258961 DOI: 10.1021/acs.joc.2c00018  0.707
2021 Rahman MS, Kumari S, Hadi Esfahani S, Nozohouri S, Jayaraman S, Kinarivala N, Kocot J, Baez A, Farris D, Abbruscato TJ, Karamyan VT, Trippier PC. Correction to "Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability". Journal of Medicinal Chemistry. PMID 34935384 DOI: 10.1021/acs.jmedchem.1c02105  0.712
2021 Rahman MS, Kumari S, Esfahani SH, Nozohouri S, Jayaraman S, Kinarivala N, Kocot J, Baez A, Farris D, Abbruscato TJ, Karamyan VT, Trippier PC. Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. Journal of Medicinal Chemistry. PMID 34436882 DOI: 10.1021/acs.jmedchem.1c00759  0.733
2020 Kinarivala N, Morsy A, Patel R, Carmona AV, Sajib MS, Raut S, Mikelis CM, Al-Ahmad A, Trippier PC. An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening. Acs Pharmacology & Translational Science. 3: 931-947. PMID 33073192 DOI: 10.1021/acsptsci.0c00077  0.748
2020 Maalouf K, Makoukji J, Saab S, Makhoul NJ, Carmona AV, Kinarivala N, Ghanem N, Trippier PC, Boustany RM. Exogenous Flupirtine as Potential Treatment for CLN3 Disease. Cells. 9. PMID 32796515 DOI: 10.3390/Cells9081872  0.731
2018 Makoukji J, Saadeh F, Mansour KA, El-Sitt S, Al Ali J, Kinarivala N, Trippier PC, Boustany RM. Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. Annals of Clinical and Translational Neurology. 5: 1089-1103. PMID 30250865 DOI: 10.1002/Acn3.625  0.739
2017 Kinarivala N, Patel R, Boustany RM, Al-Ahmad AJ, Trippier PC. Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-cell lymphoma 2 (Bcl-2). Journal of Medicinal Chemistry. PMID 29110485 DOI: 10.1021/Acs.Jmedchem.7B01199  0.759
2017 Wang H, Huwaimel B, Verma K, Miller J, Germain T, Kinarivala N, Pappas D, Brookes P, Trippier PC. Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5. Chemmedchem. PMID 28523727 DOI: 10.1002/Cmdc.201700196  0.727
2016 Kinarivala N, Shah K, Abbruscato TJ, Trippier PC. Passage Variation of PC12 Cells Results in Inconsistent Susceptibility to Externally Induced Apoptosis. Acs Chemical Neuroscience. PMID 27718545 DOI: 10.1021/Acschemneuro.6B00208  0.724
2016 Kinarivala N, Suh JH, Botros M, Webb P, Trippier PC. Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity. Bioorganic & Medicinal Chemistry Letters. PMID 26988304 DOI: 10.1016/J.Bmcl.2016.03.028  0.737
2016 Kinarivala N, Trippier PC. Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). Journal of Medicinal Chemistry. 59: 4415-27. PMID 26565590 DOI: 10.1021/Acs.Jmedchem.5B01020  0.742
2014 Trippier PC, Zhao KT, Fox SG, Schiefer IT, Benmohamed R, Moran J, Kirsch DR, Morimoto RI, Silverman RB. Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. Acs Chemical Neuroscience. 5: 823-9. PMID 25001311 DOI: 10.1021/Cn500147V  0.723
2014 Kinarivala N, Trippier PC. Exploration of relative chemoselectivity in the hydrodechlorination of 2-chloropyridines Tetrahedron Letters. 55: 5386-5389. DOI: 10.1016/J.Tetlet.2014.08.008  0.692
2014 Trippier PC, Benmohamed R, Kirsch DR, Silverman RB. Corrigendum to “Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1” [Bioorg. Med. Chem. Lett. 22 (2012) 6647–6650] Bioorganic & Medicinal Chemistry Letters. 24: 691. DOI: 10.1016/J.Bmcl.2013.12.027  0.362
2013 Trippier PC, Jansen Labby K, Hawker DD, Mataka JJ, Silverman RB. Target- and mechanism-based therapeutics for neurodegenerative diseases: Strength in numbers Journal of Medicinal Chemistry. 56: 3121-3147. PMID 23458846 DOI: 10.1021/Jm3015926  0.743
2012 Trippier PC, Benmohammed R, Kirsch DR, Silverman RB. Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1 Bioorganic and Medicinal Chemistry Letters. 22: 6647-6650. PMID 23021992 DOI: 10.1016/J.Bmcl.2012.08.114  0.45
2012 Angelov P, Chau YK, Fryer PJ, Moloney MG, Thompson AL, Trippier PC. Biomimetic synthesis, antibacterial activity and structure-activity properties of the pyroglutamate core of oxazolomycin. Organic & Biomolecular Chemistry. 10: 3472-85. PMID 22437843 DOI: 10.1039/C2Ob00042C  0.507
2011 Klaić L, Trippier PC, Mishra RK, Morimoto RI, Silverman RB. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol. Journal of the American Chemical Society. 133: 19634-7. PMID 22087583 DOI: 10.1021/Ja208359A  0.451
2011 Trippier PC, Balzarini J, McGuigan C. Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: bisphenylboronic acids. Antiviral Chemistry & Chemotherapy. 21: 129-42. PMID 21233534 DOI: 10.3851/IMP1707  0.437
2010 Trippier PC, McGuigan C, Balzarini J. Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: monophenylboronic acids. Antiviral Chemistry & Chemotherapy. 20: 249-57. PMID 20710065 DOI: 10.3851/IMP1632  0.48
2010 Trippier PC, McGuigan C. Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications Medchemcomm. 1: 183. DOI: 10.1039/C0MD00119H  0.43
2004 Moloney MG, Trippier PC, Yaqoob M, Wang Z. The oxazolomycins: a structurally novel class of bioactive compounds. Current Drug Discovery Technologies. 1: 181-99. PMID 16472256 DOI: 10.2174/1570163043334974  0.512
2003 Bulger PG, Moloney MG, Trippier PC. A multicomponent coupling strategy suitable for the synthesis of the triene component of the oxazolomycin antibiotics. Organic & Biomolecular Chemistry. 1: 3726-37. PMID 14649904 DOI: 10.1039/B306925G  0.447
Show low-probability matches.